SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia

Benzinga · 2d ago

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore.

Data to be presented will highlight the progress of SAB BIO's lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including:

  • Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142.
  • Phase 1 study data demonstrating immunomodulation without sustained lymphodepletion following dosing of SAB-142.
  • Phase 1 study data demonstrating a favorable safety profile for SAB-142, characterized as not causing serum sickness or anti-drug antibodies at the target dose.